Intracoronary abciximab did not significantly reduce all-cause mortality compared with intravenous abciximab in STEMI patients (OR 0.67; 95% CI 0.34-1.34).
Meta-Analysis (n=3,311)
Does intracoronary abciximab reduce all-cause mortality compared to intravenous abciximab in patients with STEMI?
Intracoronary administration of abciximab does not offer a mortality benefit over intravenous administration in patients with STEMI.
Estimación del efecto: OR 0.67 (95% CI 0.34-1.34)
BACKGROUND: Intracoronary (IC) abciximab administration remains a promising approach aimed to increase a drug concentration in the target area and possibly improve clinical outcomes in the setting of ST-segment elevation myocardial infarction (STEMI). The goal of this literature review and meta-analysis is to update available knowledge comparing IC and intravenous (IV) abciximab administration in STEMI patients. METHODS: A total of 7 randomized clinical trials (RCTs) with a median follow-up of 3 months were included in the meta-analysis (n = 3311). All-cause mortality was selected as the primary end point while recurrent myocardial infarction (re-MI), target vessel revascularization (TVR) and major bleeding complications were the secondary end points. RESULTS: IC abciximab did not provide any benefits in terms of all-cause mortality as compared with IV abciximab (odds ratio OR 0.67; 95% confidence interval CI 0.34-1.34). However, this neutral effect was driven by the AIDA STEMI trial. The IC route was associated with a reduced rate of re-MI when compared with IV administration (OR 0.61; 95% CI 0.40-0.92) but the difference disappeared after one of the RCTs was excluded from the analysis. Both strategies were equal regarding TVR (OR 0.66; 95% CI 0.40-1.09) and major bleeding complications (OR 1.18; 95% CI 0.76-1.83). CONCLUSIONS: Our updated meta-analysis shows that the clinical superiority of IC over IV abciximab administration in STEMI patients is no longer clear after the release of the AIDA STEMI trial results. Further research in high-risk STEMI patients is warranted to finally determine clinical advantages of IC vs IV abciximab administration.
Kubica et al. (Wed,) conducted a meta-analysis in ST-segment elevation myocardial infarction (STEMI) (n=3,311). Intracoronary (IC) abciximab vs. Intravenous (IV) abciximab was evaluated on All-cause mortality (OR 0.67, 95% CI 0.34-1.34). Intracoronary abciximab did not significantly reduce all-cause mortality compared with intravenous abciximab in STEMI patients (OR 0.67; 95% CI 0.34-1.34).